Weather Alert
Snow is in the forecast. Consider switching to a virtual visit to receive care from home. Learn more >>
Popular Search Terms
Francesca Alvarez Calderon, MD, PhD
Attending Physician, Cancer and Blood Disorders Center
Instructor of Pediatrics, Harvard Medical School
Image
Francesca Alvarez Calderon, MD, PhD
Attending Physician, Cancer and Blood Disorders Center
Instructor of Pediatrics, Harvard Medical School
Medical Services
Languages
Spanish
Education
Graduate School
University of Colorado School of Medicine
2015
Aurora
CO
Medical School
University of Colorado School of Medicine
2015
Aurora
CO
Internship
General Pediatrics
Boston Children's Hospital
2016
Boston
MA
Residency
General Pediatrics
Boston Children's Hospital
2017
Boston
MA
Fellowship
Pediatrics Hematology and Oncology
Boston Children's Hospital/Dana-Farber Cancer Institute
2021
Boston
MA
Certifications
American Board of Pediatrics (General)
American Board of Pediatrics (Hematology-Oncology)
Professional History
Francesca Alvarez Calderon, MD, PhD, is an Attending Physician in Pediatric Hematology and Oncology at Dana-Farber Cancer Institute (DFCI) and Boston Children's Hospital (BCH). She completed her MD, PhD training in the Medical Scientist Training Program at the University of Colorado School of Medicine. Dr. Alvarez Calderon completed her Pediatrics residency in the Boston Combined Residency Program and Pediatric Hematology/Oncology fellowship at DFCI/BCH. She is interested in novel cancer immunotherapies and cellular therapies to treat childhood cancer.
Publications
Umbilical Cord Blood Reduced Relapse but Increased Nonrelapse Mortality Compared to Matched Unrelated Donor Transplantation in Pediatric Acute Myeloid Leukemia With Active Disease: A CIBMTR 2008 to 2017 Analysis of Donor Source and Residual Disease. View Abstract
Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity. View Abstract
Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies. View Abstract
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. View Abstract
Oncogenic drivers and mitochondrial dependency. View Abstract
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. View Abstract
Using functional genomics to overcome therapeutic resistance in hematological malignancies. View Abstract
Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission. View Abstract
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. View Abstract
The conformation of end-groups is one determinant of carotenoid topology suitable for high fidelity molecular recognition: a study of beta- and epsilon-end-groups. View Abstract
Macular pigment response to a supplement containing meso-zeaxanthin, lutein and zeaxanthin. View Abstract